Zacks: Brokerages Expect Aratana Therapeutics Inc (PETX) Will Post Quarterly Sales of $5.72 Million

Wall Street brokerages forecast that Aratana Therapeutics Inc (NASDAQ:PETX) will announce sales of $5.72 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Aratana Therapeutics’ earnings. The highest sales estimate is $9.70 million and the lowest is $2.88 million. Aratana Therapeutics reported sales of $290,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 1,872.4%. The business is expected to issue its next quarterly earnings report on Monday, March 12th.

On average, analysts expect that Aratana Therapeutics will report full year sales of $5.72 million for the current fiscal year, with estimates ranging from $17.99 million to $24.90 million. For the next year, analysts expect that the company will report sales of $36.23 million per share, with estimates ranging from $19.28 million to $59.62 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Aratana Therapeutics.

Aratana Therapeutics (NASDAQ:PETX) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.03. The firm had revenue of $6.16 million during the quarter, compared to the consensus estimate of $6.47 million. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. The business’s quarterly revenue was up 1440.0% on a year-over-year basis. During the same period last year, the company earned ($0.38) earnings per share.

Several equities analysts have commented on PETX shares. HC Wainwright started coverage on Aratana Therapeutics in a research report on Friday, November 17th. They issued a “buy” rating and a $10.00 target price for the company. Jefferies Group set a $9.00 target price on Aratana Therapeutics and gave the company a “buy” rating in a research report on Thursday, November 16th. Zacks Investment Research upgraded Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 target price for the company in a research report on Thursday, November 9th. Stifel Nicolaus reiterated a “hold” rating and issued a $6.00 target price on shares of Aratana Therapeutics in a research report on Monday, December 18th. Finally, CL King started coverage on Aratana Therapeutics in a research report on Wednesday, December 27th. They set a “neutral” rating for the company. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $8.55.

In other news, insider Peter Steven St sold 50,000 shares of the firm’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $7.00, for a total transaction of $350,000.00. Following the completion of the transaction, the insider now directly owns 529,359 shares in the company, valued at $3,705,513. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Healthcare Master Fun Broadfin sold 116,516 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $6.53, for a total value of $760,849.48. The disclosure for this sale can be found here. Insiders have sold 1,087,032 shares of company stock valued at $6,344,891 over the last 90 days. 5.20% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Voya Investment Management LLC raised its position in shares of Aratana Therapeutics by 22.7% during the second quarter. Voya Investment Management LLC now owns 19,530 shares of the biopharmaceutical company’s stock worth $141,000 after acquiring an additional 3,610 shares during the last quarter. ProShare Advisors LLC grew its stake in Aratana Therapeutics by 7.2% during the second quarter. ProShare Advisors LLC now owns 25,322 shares of the biopharmaceutical company’s stock worth $183,000 after purchasing an additional 1,709 shares during the period. Parametric Portfolio Associates LLC grew its stake in Aratana Therapeutics by 6.6% during the second quarter. Parametric Portfolio Associates LLC now owns 30,127 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 1,875 shares during the period. The Manufacturers Life Insurance Company grew its stake in Aratana Therapeutics by 25.3% during the second quarter. The Manufacturers Life Insurance Company now owns 34,176 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 6,898 shares during the period. Finally, Rhumbline Advisers grew its stake in Aratana Therapeutics by 16.4% during the second quarter. Rhumbline Advisers now owns 48,214 shares of the biopharmaceutical company’s stock worth $349,000 after purchasing an additional 6,800 shares during the period. Institutional investors own 73.75% of the company’s stock.

Aratana Therapeutics (PETX) opened at $4.83 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.42 and a quick ratio of 3.08. The company has a market capitalization of $207.69, a PE ratio of -3.33 and a beta of 3.36. Aratana Therapeutics has a 1 year low of $4.63 and a 1 year high of $8.08.

COPYRIGHT VIOLATION WARNING: This article was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/28/zacks-brokerages-expect-aratana-therapeutics-inc-petx-will-post-quarterly-sales-of-5-72-million.html.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply